Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma

M. Kendall Bártů, K. Němejcová, R. Michálková, I. Stružinská, N. Hájková, J. Hojný, E. Krkavcová, J. Laco, R. Matěj, J. Drozenová, G. Méhes, P. Fabian, J. Hausnerová, M. Švajdler, P. Škapa, D. Cibula, T. Zima, P. Dundr

. 2023 ; 483 (4) : 497-507. [pub] 20230907

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001145

Grantová podpora
RVO VFN 64165 Ministerstvo Zdravotnictví Ceské Republiky
AZV NV19-03-00007 Ministerstvo Zdravotnictví Ceské Republiky
UNCE204065 lékařská fakulta Univerzity Karlovy
SVV260631 lékařská fakulta Univerzity Karlovy
EF16_013/0001674 European Regional Development Fund
LM2023033 BBMRI_CZ

E-zdroje Online Plný text

NLK ProQuest Central od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2003-01-01 do Před 1 rokem

Odkazy

PubMed 37676270
DOI 10.1007/s00428-023-03640-4
Knihovny.cz E-zdroje

Ovarian clear cell carcinoma (OCCC) is a subtype of ovarian carcinoma characterized by unique biological features and highly malignant characteristics including low chemosensitivity. Therefore, new therapeutic targets are needed. These could include the downstream pathways of receptor tyrosine kinases, especially the human epidermal growth factor receptor 2 (HER2). Our main objective was to characterize the HER2 status using immunohistochemistry (IHC) and FISH on 118 OCCCs, also considering the novel paradigm of HER2-zero and HER2-low status. Other aims included determination of the association between HER2 status and survival, HER2 gene DNA and RNA NGS analysis, HER2 gene expression analysis, and correlation between IHC and gene expression in HER2-zero and HER2-low cases. Cases with HER2 overexpression/amplification accounted for 5.1% (6/118), with additional 3% harbouring HER2 gene mutation. The remaining 112 (94.9%) cases were HER2-negative. Of these, 75% were classified as HER2-zero and 25% as HER2-low. This percentage of HER2 aberrations is significant concerning their possible therapeutic influence. Cases from the HER2-zero group showed significantly better survival. Although this relationship lost statistical significance in multivariate analysis, the results have potential therapeutic significance. HER2 gene expression analysis showed a significant correlation with HER2 IHC status in the entire cohort (HER2-positive vs. HER2-negative), while in the cohort of only HER2-negative cases, the results did not reach statistical significance, suggesting that gene expression analysis would not be suitable to confirm the subdivision into HER2-low and HER2-zero. Our results also emphasize the need for standardized HER2 testing in OCCC to determine the best predictor of clinical response.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001145
003      
CZ-PrNML
005      
20240213094404.0
007      
ta
008      
240109s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-023-03640-4 $2 doi
035    __
$a (PubMed)37676270
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kendall Bártů, Michaela $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic. michaela.kendallbartu@vfn.cz $1 https://orcid.org/0000000258693618 $7 xx0233216
245    10
$a HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma / $c M. Kendall Bártů, K. Němejcová, R. Michálková, I. Stružinská, N. Hájková, J. Hojný, E. Krkavcová, J. Laco, R. Matěj, J. Drozenová, G. Méhes, P. Fabian, J. Hausnerová, M. Švajdler, P. Škapa, D. Cibula, T. Zima, P. Dundr
520    9_
$a Ovarian clear cell carcinoma (OCCC) is a subtype of ovarian carcinoma characterized by unique biological features and highly malignant characteristics including low chemosensitivity. Therefore, new therapeutic targets are needed. These could include the downstream pathways of receptor tyrosine kinases, especially the human epidermal growth factor receptor 2 (HER2). Our main objective was to characterize the HER2 status using immunohistochemistry (IHC) and FISH on 118 OCCCs, also considering the novel paradigm of HER2-zero and HER2-low status. Other aims included determination of the association between HER2 status and survival, HER2 gene DNA and RNA NGS analysis, HER2 gene expression analysis, and correlation between IHC and gene expression in HER2-zero and HER2-low cases. Cases with HER2 overexpression/amplification accounted for 5.1% (6/118), with additional 3% harbouring HER2 gene mutation. The remaining 112 (94.9%) cases were HER2-negative. Of these, 75% were classified as HER2-zero and 25% as HER2-low. This percentage of HER2 aberrations is significant concerning their possible therapeutic influence. Cases from the HER2-zero group showed significantly better survival. Although this relationship lost statistical significance in multivariate analysis, the results have potential therapeutic significance. HER2 gene expression analysis showed a significant correlation with HER2 IHC status in the entire cohort (HER2-positive vs. HER2-negative), while in the cohort of only HER2-negative cases, the results did not reach statistical significance, suggesting that gene expression analysis would not be suitable to confirm the subdivision into HER2-low and HER2-zero. Our results also emphasize the need for standardized HER2 testing in OCCC to determine the best predictor of clinical response.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a amplifikace genu $7 D005784
650    _2
$a receptor erbB-2 $x metabolismus $7 D018719
650    12
$a nádory vaječníků $x patologie $7 D010051
650    _2
$a epiteliální ovariální karcinom $x genetika $7 D000077216
650    _2
$a imunohistochemie $7 D007150
650    12
$a nádory prsu $x genetika $7 D001943
655    _2
$a časopisecké články $7 D016428
700    1_
$a Němejcová, Kristýna $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic
700    1_
$a Michálková, Romana $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic
700    1_
$a Stružinská, Ivana $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic
700    1_
$a Hájková, Nikola $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic
700    1_
$a Hojný, Jan $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic
700    1_
$a Krkavcová, Eva $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Matěj, Radoslav $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Drozenová, Jana $u Department of Pathology, 3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 10034, Prague, Czech Republic
700    1_
$a Méhes, Gábor $u Department of Pathology, Faculty of Medicine, University of Debrecen, 4032, Debrecen, Hungary
700    1_
$a Fabian, Pavel $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Hausnerová, Jitka $u Department of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
700    1_
$a Švajdler, Marián $u Šikl's Department of Pathology, The Faculty of Medicine and Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Škapa, Petr $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic
700    1_
$a Cibula, David $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Zima, Tomáš $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Dundr, Pavel $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, 12800 Prague 2, Prague, Czech Republic
773    0_
$w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 483, č. 4 (2023), s. 497-507
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37676270 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094401 $b ABA008
999    __
$a ok $b bmc $g 2049631 $s 1210839
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 483 $c 4 $d 497-507 $e 20230907 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
GRA    __
$a RVO VFN 64165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a AZV NV19-03-00007 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a UNCE204065 $p lékařská fakulta Univerzity Karlovy
GRA    __
$a SVV260631 $p lékařská fakulta Univerzity Karlovy
GRA    __
$a EF16_013/0001674 $p European Regional Development Fund
GRA    __
$a LM2023033 $p BBMRI_CZ
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace